|
1
|
Aldera AP and Govender D: Gene of the
month: SDH. J Clin Pathol. 71:95–97. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bardella C, Pollard PJ and Tomlinson I:
SDH mutations in cancer. Biochim Biophys Acta. 1807:1432–1443.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gill AJ: Succinate dehydrogenase
(SDH)-deficient neoplasia. Histopathology. 72:106–116. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vanharanta S, Buchta M, McWhinney SR,
Virta SK, Peçzkowska M, Morrison CD, Lehtonen R, Januszewicz A,
Järvinen H, Juhola M, et al: Early-onset renal cell carcinoma as a
novel extraparaganglial component of SDHB-associated heritable
paraganglioma. Am J Hum Genet. 74:153–159. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Srigley JR, Delahunt B, Eble JN, Egevad L,
Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, et
al: The international society of urological pathology (ISUP)
vancouver classification of renal neoplasia. Am J Surg Pathol.
37:1469–1489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moch H, Cubilla AL, Humphrey PA, Reuter VE
and Ulbright TM: The 2016 WHO classification of tumours of the
urinary system and male genital organs-part A: Renal, penile, and
testicular tumours. Eur Urol. 70:93–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gill AJ, Hes O, Papathomas T, Šedivcová M,
Tan PH, Agaimy A, Andresen PA, Kedziora A, Clarkson A, Toon CW, et
al: Succinate dehydrogenase (SDH)-deficient renal carcinoma: A
morphologically distinct entity: a clinicopathologic series of 36
tumors from 27 patients. Am J Surg Pathol. 38:1588–1602. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Williamson SR, Eble JN, Amin MB, Gupta NS,
Smith SC, Sholl LM, Montironi R, Hirsch MS and Hornick JL:
Succinate dehydrogenase-deficient renal cell carcinoma: Detailed
characterization of 11 tumors defining a unique subtype of renal
cell carcinoma. Mod Pathol. 28:80–94. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsai TH and Lee WY: Succinate
dehydrogenase-deficient renal cell carcinoma. Arch Pathol Lab Med.
143:643–647. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McEvoy CR, Koe L, Choong DY, Leong HS, Xu
H, Karikios D, Plew JD, Prall OW, Fellowes AP and Fox SB:
SDH-deficient renal cell carcinoma associated with biallelic
mutation in succinate dehydrogenase A: Comprehensive genetic
profiling and its relation to therapy response. NPJ Precis Oncol.
2:92018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yakirevich E, Ali SM, Mega A, McMahon C,
Brodsky AS, Ross JS, Allen J, Elvin JA, Safran H and Resnick MB: A
novel SDHA-deficient renal cell carcinoma revealed by comprehensive
genomic profiling. Am J Surg Pathol. 39:858–863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ozluk Y, Taheri D, Matoso A, Sanli O,
Berker NK, Yakirevich E, Balasubramanian S, Ross JS, Ali SM and
Netto GJ: Renal carcinoma associated with a novel succinate
dehydrogenase A mutation: A case report and review of literature of
a rare subtype of renal carcinoma. Hum Pathol. 46:1951–1955. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang Q, Zhang Y, Zhou YH, Hou YY, Wang
JY, Li JL, Li M, Tong HX and Lu WQ: A novel germline mutation in
SDHA identified in a rare case of gastrointestinal stromal tumor
complicated with renal cell carcinoma. Int J Clin Exp Pathol.
8:12188–12197. 2015.PubMed/NCBI
|
|
14
|
Wang Y, He P, Zhou X, Wang C, Fu J, Zhang
D, Liao D, Zhou Z, Wu C and Gong W: Gene mutation profiling and
clinical significances in patients with renal cell carcinoma.
Clinics (Sao Paulo). 78:1002592023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fuchs TL, Maclean F, Turchini J, Vargas
AC, Bhattarai S, Agaimy A, Hartmann A, Kao CS, Ellis C, Bonert M,
et al: Expanding the clinicopathological spectrum of succinate
dehydrogenase-deficient renal cell carcinoma with a focus on
variant morphologies: A study of 62 new tumors in 59 patients. Mod
Pathol. 35:836–849. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
WHO Classification of Tumours Editorial
Board, . Urinary and male genital tumours: WHO classification of
tumours. 5th edition. Vol 8. International Agency for Research on
Cancer; Lyon, France: 2022
|
|
17
|
Kamai T, Higashi S, Murakami S, Arai K,
Namatame T, Kijima T, Abe H, Jamiyan T, Ishida K, Shirataki H and
Yoshida KI: Single nucleotide variants of succinate dehydrogenase A
gene in renal cell carcinoma. Cancer Sci. 112:3375–3387. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Argani P, Hawkins A, Griffin CA, Goldstein
JD, Haas M, Beckwith JB, Mankinen CB and Perlman EJ: A distinctive
pediatric renal neoplasm characterized by epithelioid morphology,
basement membrane production, focal HMB45 immunoreactivity, and
t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol.
158:2089–2096. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Akgul M, Williamson SR, Ertoy D, Argani P,
Gupta S, Caliò A, Reuter V, Tickoo S, Al-Ahmadie HA, Netto GJ, et
al: Diagnostic approach in TFE3-rearranged renal cell carcinoma: A
multi-institutional international survey. J Clin Pathol.
74:291–299. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang XM, Shao L, Xiao H, Myers JL,
Pantanowitz L, Skala SL, Udager AM, Vaishampayan U, Mannan R,
Dhanasekaran SM, et al: Lessons from 801 clinical TFE3/TFEB
fluorescence in situ hybridization assays performed on renal cell
carcinoma suspicious for MiTF family aberrations. Am J Clin Pathol.
160:549–554. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Smith SC, Sirohi D, Ohe C, McHugh JB,
Hornick JL, Kalariya J, Karia S, Snape K, Hodgson SV, Cani AK, et
al: A distinctive, low-grade oncocytic fumarate hydratase-deficient
renal cell carcinoma, morphologically reminiscent of succinate
dehydrogenase-deficient renal cell carcinoma. Histopathology.
71:42–52. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tjota M, Chen H, Parilla M, Wanjari P,
Segal J and Antic T: Eosinophilic renal cell tumors with a TSC and
MTOR gene mutations are morphologically and immunohistochemically
heterogenous: Clinicopathologic and Molecular Study. Am J Surg
Pathol. 44:943–954. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lalani AA, Heng DYC, Basappa NS, Wood L,
Iqbal N, McLeod D, Soulières D and Kollmannsberger C: Evolving
landscape of first-line combination therapy in advanced renal
cancer: A systematic review. Ther Adv Med Oncol.
14:175883592211086852022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moran M, Nickens D, Adcock K, Bennetts M,
Desscan A, Charnley N and Fife K: Sunitinib for metastatic renal
cell carcinoma: A systematic review and meta-analysis of real-world
and clinical trials data. Target Oncol. 14:405–416. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aggen DH, Drake CG and Rini BI: Targeting
PD-1 or PD-L1 in metastatic kidney cancer: Combination therapy in
the first-line setting. Clin Cancer Res. 26:2087–2095. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brown JE, Royle KL, Gregory W, Ralph C,
Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R, et
al: Temporary treatment cessation versus continuation of first-line
tyrosine kinase inhibitor in patients with advanced clear cell
renal cell carcinoma (STAR): An open-label, non-inferiority,
randomised, controlled, phase 2/3 trial. Lancet Oncol. 24:213–227.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choueiri TK, Powles T, Peltola K, de
Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET,
Verzoni E, et al: Belzutifan versus everolimus for advanced
renal-cell carcinoma. N Engl J Med. 391:710–721. 2024. View Article : Google Scholar : PubMed/NCBI
|
